Evidence map›Paper›PMID 35687264›Full record

ArticleStem cell reviews and reports2022

Expansion of Human Megakaryocyte-Lineage Progeny via Aryl Hydrocarbon Receptor Antagonism with CH223191.

Dongchan Kim, Dong-Yeop Shin, Jun Liu, Na-Rae Jeong, Youngil Koh, Junshik Hong, Xinxin Huang, Hal E Broxmeyer, Sung-Soo Yoon

Abstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Effect of Sheng Xuexiaoban capsules on Tregs in an ITP mouse model.Annals of medicine and surgery (2012) · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Dongchan KimCancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Dong-Yeop ShinCancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. shindongyeop@snu.ac.kr.
Jun LiuCancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Na-Rae JeongCancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Youngil KohCancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Junshik HongCancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Xinxin HuangInstitutes of Biomedical Sciences, Fudan University, Shanghai, China.
Hal E BroxmeyerDepartment of Microbiology and Immunology, Indiana University School of Medicine (IUSM), Indianapolis, IN, USA.
Sung-Soo YoonCancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. ssysmc@snu.ac.kr.
Seoul National University · KRSeoul National University Hospital · KRFudan University · CNIndiana University School of MedicineNew Generation University College · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aryl hydrocarbon receptor (AhR) antagonism is known to expand human hematopoietic stem cells (HSCs). However, its regulatory effect on the lineage-skewed differentiation of HSCs has not been sufficiently studied. Here, we investigate the effect of the AhR-selective antagonist CH223191 on the regulation of HSC differentiation. Consistent with the well-known effects of AhR antagonists, CH223191 treatment increase phenotypic HSCs (Lin-CD34 + CD38-CD90 + CD45RA-) and preserves their functionality. On the other hand, CH223191 leads to an overall expansion of megakaryocyte (MK)-lineage populations, such as MK progenitors (MKps, CD34 + CD41 +), immature MKs (CD41 + CD42b-), and mature MKs (CD41 + CD42b +), and it also activates MK/platelet-associated signaling pathways. Furthermore, CH223191 expands MKps, mature MKs, and p-selectin (CD62p)-positive platelet-like particles in immune thrombocytopenia (ITP) patient bone marrow (BM). These results highlight the numerical expansion of human MK-lineage progeny through AhR antagonism with CH223191. This approach using CH2231291 may be applicable in the development of auxiliary treatment regimens for patients with abnormal thrombopoiesis.

Indexed as

MegakaryocytesReceptors, Aryl HydrocarbonAntigens, CD34Azo CompoundsCell LineageHumansPyrazoles2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amideAntigens, CD34Azo CompoundsPyrazolesReceptors, Aryl HydrocarbonAryl Hydrocarbon Receptors (AhRs)Cell DifferentiationHematopoiesisHematopoietic Stem Cells (HSCs)Immune Thrombocytopenia (ITP)Megakaryocytes

Identifiers

PMID35687264
OpenAlexW4281841968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.